In 2024–25, the MHRA conducted 353 GMP inspections, showing how closely regulators continue to examine pharmaceutical quality systems. As companies rely more on digital tools, software controls now shape the reliability of records, decisions, and batch evidence. However, pharma software development must go beyond functionality and address validation, access control, audit trails, and data integrity from the start.
Therefore, digitalization in pharma industry requires systems that remain controlled, traceable, and inspection-ready throughout their lifecycle. This guide explains the key GMP validation and compliance principles pharmaceutical teams should understand before developing or changing regulated software.
Table of Contents
What Is Pharma Software Development in a GMP Environment?
Pharmaceutical software development covers much more than building a functional digital tool. It includes system design, configuration, testing, validation, deployment, maintenance, and controlled retirement. In a GMP environment, each stage must protect product quality and reliable data. Therefore, teams must define requirements and risks before the system goes live. They must also maintain documented control throughout its lifecycle. As a result, well-managed pharma software supports consistent processes, traceable records, and inspection readiness across regulated operations.
Why Pharma Software Becomes a GMP Inspection Issue?
Pharma software becomes a GMP inspection issue when it affects product quality, regulated records, or critical decisions. Inspectors therefore look beyond whether a system simply works. They examine who can access data, how changes are recorded, and whether audit trails remain complete. In addition, weak validation or uncontrolled configuration changes can undermine data integrity. As a result, companies must show clear evidence that their software remains secure, traceable, validated, and under control throughout its lifecycle.
This infographic highlights eight software controls that help pharmaceutical teams protect data integrity, maintain traceability, and prepare for GMP inspections.
Four Essential Controls for Inspection-Ready Pharma Software
Inspection-ready pharma software depends on more than successful installation and testing. Teams must define risk early, document requirements clearly, and control how data moves through the system. In addition, they must understand when 21 CFR Part 11 applies and protect critical electronic records. Therefore, strong validation connects system design, traceability, access control, audit trails, and backups across the full software lifecycle.
The following four controls show where pharmaceutical teams should focus to keep software validated, traceable, secure, and inspection-ready throughout its lifecycle.
- Define Intended Use and Risk Before Validation (PDF)
- Build Requirements, Traceability, and Supplier Control (PDF)
- Determine When 21 CFR Part 11 Applies (PDF)
- Protect Data Integrity, Audit Trails, and Backups (PDF)
Define Intended Use and Risk Before Validation (PDF)
Define the system’s intended use before deciding how much validation evidence it requires.
Then apply a risk-based approach that considers GxP impact, complexity, product quality, and data integrity.
Download Validation of computerized systems Here
Build Requirements, Traceability, and Supplier Control (PDF)
Clear user requirements should define what the computerized system must achieve within the regulated process. In addition, teams should maintain lifecycle traceability and assess suppliers according to system risk and responsibility.
Download Annex 11: Computerised Systems Here
Determine When 21 CFR Part 11 Applies (PDF)
Determine whether regulated activities rely on electronic records or electronic signatures covered by FDA requirements. Then distinguish Part 11 controls from the underlying predicate rules that require those records to be maintained.
Download Part 11, Electronic Records; Electronic Signatures — Scope and Application Here
Protect Data Integrity, Audit Trails, and Backups (PDF)
Keep GMP data complete, secure, and traceable. Control access, audit trails, and backups.
Download Data Integrity and Compliance With Drug CGMP: Questions and Answers — Guidance for Industry Here
How GAMP 5, Annex 11, and Part 11 Fit Together
GAMP 5, EU GMP Annex 11, and 21 CFR Part 11 support compliant computerized systems, but they serve different purposes. GAMP 5 provides an industry framework for risk-based lifecycle management, while Annex 11 defines EU GMP expectations for computerized systems. In contrast, Part 11 sets US regulatory requirements for qualifying electronic records and electronic signatures. Therefore, pharmaceutical teams should apply them together where relevant rather than treat them as interchangeable standards.
The table below shows how each framework differs in status, scope, key controls, and the evidence pharmaceutical teams may need to demonstrate.
| Framework | What It Is | Main Scope | Key Software Controls | Typical Evidence |
|---|---|---|---|---|
|
GAMP 5 |
Industry good-practice guidance from ISPE |
Risk-based lifecycle management of GxP computerized systems |
Intended use, risk assessment, requirements, testing, supplier management, lifecycle control |
Risk assessments, requirements, traceability, test evidence, validation records |
|
EU GMP Annex 11 |
EU GMP guidance for computerized systems |
Computerized systems used in GMP-regulated activities |
Validation, data integrity, access control, audit trails, backups, suppliers, change control, periodic review |
Validation documents, user requirements, access records, audit-trail review, backup tests, change records |
|
21 CFR Part 11 |
US FDA regulation |
Electronic records and electronic signatures subject to FDA requirements |
System controls, electronic signatures, record integrity, access, audit trails, record retention |
Validated-system evidence, controlled access, electronic-signature records, audit trails, retrievable electronic records |
As of September 2026, the European Commission still lists the January 2011 Annex 11 as the applicable version; the expanded Annex 11 published for consultation in 2025 remains a draft rather than the effective text.
How to Build Inspection Readiness Into Development
Inspection readiness should begin before validation or go-live. Teams must define controls early, manage testing and changes, and maintain compliance throughout the software lifecycle. This approach reduces control gaps and creates stronger evidence for GMP inspections.
This infographic shows how pharmaceutical software validation moves from requirements and risk assessment through testing, release, change control, and periodic review.
Final Words
FDA reported a 21% increase in inspection-based drug-quality warning letters in FY2024. This trend shows that regulators continue to examine how companies control critical quality systems and records. Therefore, pharma software development must build validation, data integrity, and traceability into the full system lifecycle. As regulatory scrutiny continues, inspection-ready software requires clear controls and reliable evidence.
Qualification and Validation for GMP Systems
Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.
FAQ
No. Part 11 generally applies when FDA-required records are maintained electronically instead of paper records, or when qualifying electronic signatures are used.
Companies should have documented intended use, requirements, risk assessments, traceability, testing results, approvals, deviations, and evidence that the system remains validated.
There is no single fixed frequency. Review should follow documented risk assessment and occur as part of routine data review when audit-trail information is relevant to GxP decisions.
References
Marco Klinger is Head of Quality Services at Zamann Pharma Support, where he leads consulting teams through complex regulatory and quality-driven projects. He brings more than 15 years of hands-on compliance experience across regulated industries. His work includes close collaboration with companies such as Reckitt, Sanofi, Biotech, Biotest, and others. Marco has deep expertise in medical device development, aseptic manufacturing, and the design, implementation, and management of complete quality management systems within GMP-regulated environments.